Congenital hyperinsulinism (CH) is a rare genetic condition characterized by increased and unregulated insulin secretion from pancreatic beta cells, leading to recurrent episodes of low blood sugar (hypoglycemia) in infants and children. Treatments for CH include diazoxide, a sulfonamide derivative that blocks insulin release from the beta cells, and occasionally octreotide, a somatostatin analog that also blocks insulin secretion. However, there remains a need for new, more effective treatments for children who do not respond adequately to medical therapy.
​
The global Congenital Hyperinsulinism Treatment market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The opportunity of increasing new product launches is expected to drive the growth of the congenital hyperinsulinism treatment market. Companies are increasingly focused on developing new drugs and treatment options for congenital hyperinsulinism (CH) with better efficacy and safety profiles. In recent years, several pharmaceutical companies have received designations and initiated clinical trials for potential first-in-class drugs to treat CH including Eiger BioPharmaceuticals' Zunsemetinib and Zealand Pharma's dasiglucagon. If approved, these new drugs will expand treatment options beyond existing somatostatin analogs and diazoxide, providing more effective control of hypoglycemia in children with CH. This new product pipeline is anticipated to propel the market growth over the forecast period.

Porter's Analysis

Threat of new entrants: Low. High capital requirements and stringent regulations pose barriers for new companies. However, high unmet needs provide opportunities.

Bargaining power of buyers: High. Presence of many treatment options gives buyers bargaining power. They can negotiate on price and quality.

Bargaining power of suppliers: Moderate. Few main suppliers for active pharmaceutical ingredients and manufacturing equipment. Suppliers differ by capabilities.

Threat of new substitutes: Moderate. Alternate disease management options exist. Research on new innovative therapies can lead to substitutes.

Competitive rivalry: High. Intense competition among existing players to gain market share. Companies compete on treatment effectiveness, pricing and safety profiles.

SWOT Analysis

Strengths: High unmet needs, advancing research, supportive regulatory environment.

Weaknesses: Lack of disease awareness, high treatment costs, risk of hypoglycemia.

Opportunities: Large patient pool, emerging economies, pipeline therapies, technological advancements.

Threats: Patent expiries, reimbursement hurdles, stringent regulations.

Key Takeaways

The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth during the forecast period. North America currently dominates the market due to established healthcare systems and supportive insurance plans. However, Asia Pacific is likely to grow at a high CAGR owing to rising healthcare investments and increasing diagnosis rates.

Key players operating in the Congenital Hyperinsulinism Treatment market are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals.,Crinetics Pharmaceuticals, Inc., AmideBio,LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd. Zealand Pharma A/S and Eli Lilly are market leaders based on their broad product portfolios and global presence.

For More Insights, Read: https://www.newswirestats.com/congenital-hyperinsulinism-treatment-market-demand-growth-and-regional-outlook-by-2030/